Retatrutide peptide is an investigational once-weekly triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors and is being studied for obesity, type 2 diabetes, and related metabolic conditions. Clinical trials have reported large reductions in body weight and improvements in glycemic and liver-fat measures, but Retatrutide remains unapproved and its long-term safety profile is still being evaluated.
